CDT Equity (NASDAQ:CDT) Trading Down 4.7% – Time to Sell?

CDT Equity Inc. (NASDAQ:CDT) shares dropped 4.7% during mid-day trading on Thursday . The company traded as low as $0.9110 and last traded at $1.01. Approximately 246,378 shares were traded during trading, a decline of 79% from the average daily volume of 1,186,239 shares. The stock had previously closed at $1.06.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CDT Equity in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

CDT Equity Price Performance

The stock has a market capitalization of $1.65 million, a price-to-earnings ratio of 0.00 and a beta of 1.80. The firm’s fifty day moving average is $1.48 and its 200-day moving average is $5.40.

CDT Equity (NASDAQ:CDT) last released its earnings results on Thursday, November 13th. The company reported ($13.16) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in CDT Equity stock. Apollon Wealth Management LLC bought a new stake in shares of CDT Equity Inc. (NASDAQ:CDT) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 107,454 shares of the company’s stock, valued at approximately $73,000. Apollon Wealth Management LLC owned about 28.28% of CDT Equity at the end of the most recent quarter. Institutional investors and hedge funds own 3.29% of the company’s stock.

About CDT Equity

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.